Boreal Genomics is a life sciences company providing research tools and developing diagnostic tests based on non-invasive tumor profiling and monitoring of cancer. Boreal's OnTarget platform performs highly sensitive genomic analysis of cell-free DNA in plasma to detect and quantify mutations in tumor-derived circulating nucleic acids. The OnTarget assay is currently available through both service and instrument offerings for research use only providing single molecule sensitivity, high specificity and multiplexing across many targets into a single test.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
10/07/13 | $18,000,000 | Series C |
ARCH Venture Partners Kearny Venture Partners | undisclosed |